Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

In this chapter of Business of Biotech episode 252, Alnylam Chief Commercial Officer Tolga Tanguler shares on the company's strategy to pivot its RNAi therapeutic applications from rare to large ...

Throughout his 25-year pharmaceutical career, he has worked in a variety of fields, including Oral Dosage Formulation Development, Quality Compliance/Assurance, Manufacturing Science & Technology, ...

Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, discusses the global opportunity for the commercialization of RNAi therapies with host Ben Comer. Catch the full episode ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based 'Newco,' explain experts at Orrick.

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discusses overcoming adversity while leading the company through challenging times.

<p data-pm-slice="1 1 []">Mental health has become one of the significant factors determining early retirement, disability benefits, absenteeism levels, and high societal costs such as productivity ...

<p>Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.</p> ...